Gemcitabine and Nab-Paclitaxel Dosing and Schedule
For metastatic pancreatic cancer, administer nab-paclitaxel 125 mg/m² followed by gemcitabine 1000 mg/m² intravenously on days 1,8, and 15 of each 28-day cycle. This is the FDA-approved regimen that demonstrated superior survival outcomes in the landmark MPACT trial 1, 2.
Standard Dosing Regimen
The established dosing schedule is:
- Nab-paclitaxel: 125 mg/m² IV over 30 minutes
- Gemcitabine: 1000 mg/m² IV over 30 minutes (administered after nab-paclitaxel)
- Schedule: Days 1,8, and 15 of a 28-day cycle
- Continue until: Disease progression or unacceptable toxicity 1
This regimen achieved a median overall survival of 8.5 months versus 6.7 months with gemcitabine alone, with 1-year survival of 35% versus 22% 2.
Dose Modifications for Toxicity
Hematologic Toxicity on Treatment Day
Day 1 dosing:
- ANC ≥1500 × 10⁶/L AND platelets ≥100,000 × 10⁶/L: Give full dose
- ANC <1500 × 10⁶/L OR platelets <100,000 × 10⁶/L: Hold treatment 1
Day 8 and 15 dosing:
- ANC ≥1200 × 10⁶/L AND platelets >75,000 × 10⁶/L: Give full dose
- ANC 1000-1199 × 10⁶/L OR platelets 50,000-75,000 × 10⁶/L: Give 75% of dose
- ANC 700-999 × 10⁶/L AND platelets ≥50,000 × 10⁶/L: Give 50% of dose
- ANC <700 × 10⁶/L OR platelets <50,000 × 10⁶/L: Hold treatment 1
Non-Hematologic Toxicity
For grade 3-4 non-hematologic toxicity (excluding nausea/vomiting controlled by antiemetics):
- Hold both drugs until toxicity resolves to ≤grade 1
- Resume at reduced doses per protocol 1
Peripheral neuropathy: Grade 3 neuropathy occurred in 17% of patients but improved to grade 1 or lower in a median of 29 days, indicating reversibility 2.
Alternative Dosing Schedules
Biweekly Schedule
An alternative regimen uses:
- Gemcitabine: 1500 mg/m² IV
- Nab-paclitaxel: 175 mg/m² IV
- Schedule: Every 2 weeks
This maintains similar dose density with median PFS of 5 months and OS of 10 months, offering logistical advantages 3.
Modified Schedule for Older Adults
Critical caveat: Real-world data shows that reducing to a 2-dose-per-cycle schedule (days 1 and 8 only) in older adults resulted in significantly shorter time on treatment (3.26 vs 4.18 months) and worse overall survival (7.63 vs 9.44 months) compared to the standard 3-dose schedule 4. Maintain the full days 1,8,15 schedule whenever possible, even in older patients, as dose intensity appears critical for efficacy.
Context-Specific Recommendations
Pancreatic Cancer (First-Line)
The combination is a Category 1 preferred regimen for patients with:
Other Indications
The evidence provided focuses on pancreatic cancer. For breast cancer, the FDA-approved gemcitabine dose with paclitaxel (not nab-paclitaxel) is 1250 mg/m² on days 1 and 8 of 21-day cycles 1.
Key Safety Considerations
Most common grade 3-4 toxicities 2:
- Neutropenia: 38% (febrile neutropenia 3%)
- Fatigue: 17%
- Peripheral neuropathy: 17%
Monitor closely: Complete blood counts before each dose, with dose modifications as outlined above. Growth factor support may be considered for recurrent neutropenia, though routine prophylaxis was not required in the pivotal trial 2.